Impact of asthma-associated genetic polymorphisms on the efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma
作者
Ilka Hoof,Klaus Bønnelykke,Marianne Witten,Thomas Stranzl,Xingnan Li,Deborah A. Meyers,Eugene R. Bleecker,Peter Sejer Andersen
出处
期刊:The European respiratory journal [European Respiratory Society] 日期:2021-09-05卷期号:: OA1483-OA1483
标识
DOI:10.1183/13993003.congress-2021.oa1483
摘要
Allergy to house dust mites (HDM) is a common cause of allergic asthma and can be effectively treated with allergy immunotherapy (AIT). Specific single-nucleotide polymorphisms (SNPs) have been associated with asthma, and specifically for the 17q12-21 locus, this association has been shown to be modifiable by environmental factors. The aim of this study was to test whether asthma-associated SNPs have an impact on the response to AIT. MITRA (Clinicaltrialsregister.eu 2010-018621-19) was a phase III, randomized, double-blind, placebo-controlled trial of HDM sublingual immunotherapy (SLIT)-tablets in adults with HDM allergic asthma. A post-hoc analysis of the MITRA study population evaluated associations between 22 asthma-risk SNPs and the primary study endpoint (time to first moderate/severe asthma exacerbation) in 582 genotyped patients. SNP rs7216389, located in the chromosomal region 17q12-21, showed a significant interaction with treatment (P=0.037): While the overall patient population had a relative risk reduction in moderate-severe asthma exacerbations (N=582, HR=0.65, 95% CI [0.48, 0.89]; P=0.008), patients homozygous for the risk allele had an even greater risk reduction (N=173, HR=0.37 [0.22, 0.64], P<0.001). The association of rs7216389 with exacerbation risk in HDM-sensitized asthmatics was verified in an independent SARP3 patient cohort (N=160, β=0.38 [0.04, 0.73], P=0.03). Our results indicate that HDM SLIT-tablet AIT is efficacious in HDM-sensitized asthma patients with a genetic predisposition to asthma. Therefore, our findings have the potential to form the basis for prospective asthma prevention strategies.